Charts
- Vaccination Recommendations for Updated 2023-2024 COVID-19 Vaccines (Updated March 11, 2024)
- Treatment of COVID-19 in High-Risk Outpatients (Updated July 18, 2023)
- COVID-19 Vaccine Comparison Chart (Archived; last updated March 15, 2023)
- Treatments Considered for COVID-19 (Archived; last updated April 1, 2022)
Articles
Vaccines
- COVID-19 Update: Novavax Vaccine for 2024-2025 (October 28, 2024)
- COVID-19 Update: New Pfizer and Moderna Vaccine Formulations for 2024-2025 (September 16, 2024)
- COVID-19 Update: An EUA for Pemivibart (Pemgarda) for Pre-Exposure Prophylaxis (May 13, 2024)
- COVID-19 Update: New Novavax Vaccine Formulation for 2023-2024 (November 13, 2023)
- COVID-19 Update: New Pfizer and Moderna Vaccine Formulations for 2023-2024 (October 16, 2023)
- COVID-19 Update: FDA Expands Bivalent Vaccine Use, Revises Vaccination Schedules (May 1, 2023)
- COVID-19 Update: Pfizer Bivalent Vaccine Booster Dose for Children 6 Months to 4 Years Old (April 3, 2023)
- COVID-19 Update: Bivalent Pfizer and Moderna Vaccines Authorized for Children ≥6 Months Old (December 12, 2022)
- COVID-19 Update: Novavax Vaccine Authorized for Booster Immunization (October 31, 2022)
- COVID-19 Update: Bivalent Vaccine Booster Doses Authorized for Children ≥5 Years Old (October 14, 2022)
- COVID-19 Update: Bivalent Pfizer and Moderna COVID-19 Vaccines for Booster Immunization (October 3, 2022)
- COVID-19 Update: Novavax Vaccine Authorized for Adolescents 12-17 Years Old (August 30, 2022)
- COVID-19 Update: FDA Authorizes Novavax COVID-19 Vaccine (August 8, 2022)
- COVID-19 Update: COVID-19 Update: Pfizer/BioNTech and Moderna Vaccines Authorized for Children ≥6 Months Old (July 11, 2022)
- COVID-19 Update: Booster Dose of the Pfizer Vaccine for Children 5-11 Years Old (June 13, 2022)
- COVID-19 Update: FDA Narrows EUA for the Johnson & Johnson Vaccine (June 13, 2022)
- COVID-19 Update: Second Booster Vaccine Dose for Older and Immunocompromised Persons (April 18, 2022)
- COVID-19 Updates: Primary-Series Dosing Interval for mRNA Vaccines, Booster Immunization in Persons Who Are Immunocompromised (March 21, 2022)
- COVID-19 Update: Moderna COVID-19 Vaccine (Spikevax) Gains Full Licensure (February 21, 2022)
- COVID-19 Update: Pfizer-BioNTech COVID-19 Vaccine (January 24, 2022)
- In Brief: Booster Doses of mRNA-Based COVID-19 Vaccines for All Adults
- In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Children 5-11 Years Old
- Booster Doses of COVID-19 Vaccines
- Booster Dose of the Pfizer/BioNTech COVID-19 Vaccine (Comirnaty)
- In Brief: Third Dose of mRNA-based COVID-19 Vaccines for Immunocompromised Persons
- In Brief: Guillain-Barré Syndrome with the Johnson & Johnson COVID-19 Vaccine
- In Brief: Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 Vaccines (online only)
- In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Adolescents 12-15 Years Old
- In Brief: Suspension of Johnson & Johnson COVID-19 Vaccine Lifted (online only)
- In Brief: Johnson & Johnson COVID-19 Vaccine Suspended (online only)
- FDA Authorizes Johnson & Johnson COVID-19 Vaccine
- FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine
- FDA Authorizes Moderna COVID-19 Vaccine
Antiviral Drugs
- Antiviral Drugs for COVID-19 in Vaccinated Outpatients (March 6, 2023)
- COVID-19 Update: Prescription of Paxlovid by Pharmacists (August 8, 2022)
- COVID-19 Update: NIH Recommends Against Ivermectin (June 13, 2022)
- COVID-19 Update: Remdesivir (Veklury) FDA-Approved for Children <12 Years Old (June 13, 2022)
- Paxlovid for Treatment of COVID-19
- Molnupiravir – An Oral Antiviral Drug for COVID-19
- Remdesivir (Veklury) for COVID-19
- Timing of Remdesivir for COVID-19
- COVID-19 Updates: Remdesivir (Veklury) in High-Risk Outpatients with COVID-19, NIH Outpatient Treatment Guidelines (February 21, 2022)
Monoclonal Antibodies
- COVID-19 Update: An EUA for Vilobelimab (Gohibic) for COVID-19 (May 29, 2023)
- COVID-19 Update: Metformin to Prevent Long Covid? (May 29, 2023)
- COVID-19 Update: Evusheld Unlikely to Neutralize XBB.1.5 Omicron Variant (January 13, 2023)
- COVID-19 Update: Tocilizumab (Actemra) FDA-Approved for Treatment of COVID-19 (January 9, 2023)
- COVID-19 Update: Bebtelovimab EUA Withdrawn (December 26, 2022)
- COVID-19 Update: Dosing Interval for Tixagevimab/Cilgavimab (Evusheld) (August 8, 2022)
- COVID-19 Update: Hypersensitivity Reactions with Tixagevimab/Cilgavimab (Evusheld) (July 11, 2022)
- COVID-19 Update: FDA Restricts Use of Sotrovimab (April 18, 2022)
- COVID-19 Update: Increased Dosage of Tixagevimab/Cilgavimab (Evusheld) (March 21, 2022)
- An EUA for Bebtelovimab for Treatment of COVID-19
- COVID-19 Update: Monoclonal Antibodies for COVID-19 (January 24, 2022)
- Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19
- Bamlanivimab and Etesevimab for Post-Exposure Prophylaxis of COVID-19
- Casirivimab and Imdevimab (REGEN-COV) for Post-Exposure Prophylaxis of COVID-19
- An EUA for Tocilizumab (Actemra) for COVID-19
- An EUA for Sotrovimab for Treatment of COVID-19
- An EUA for Bamlanivimab and Etesevimab for COVID-19
- An EUA for Bamlanivimab – A Monoclonal Antibody for COVID-19
- An EUA for Casirivimab and Imdevimab for COVID-19
Other Drugs
- An EUA for Anakinra (Kineret) for COVID-19 (December 12, 2022)
- COVID-19 Update: Baricitinib (Olumiant) FDA-Approved for Treatment of COVID-19 (June 13, 2022)
- Fluvoxamine for COVID-19?
- An EUA for Baricitinib (Olumiant) for COVID-19
Some Helpful Resources
- National Institutes of Health — Coronavirus Disease 2019 (COVID-19) Treatment Guidelines
- US Centers for Disease Control and Prevention — Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19)
- Infectious Diseases Society of America — Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
- Surviving Sepsis Campaign — COVID-19 Guidelines
- BMJ Best Practice — Coronavirus Disease 2019 (COVID-19)
- Office of the Assistant Secretary for Preparedness & Response — List of locations that have received shipments of U.S. Govt-procured COVID-19 therapeutics
- University of Liverpool — COVID-19 drug interactions